Here is the adapted text for the UK Natural Medicine industry, updated to reflect the data and timeline for April 2026.

The inventionINDEX measures innovation output by comparing industry revenue growth with patent production growth. Anything over a C grade is positive sentiment; anything under C is a negative outlook/sentiment. Using that sentiment, it is possible to observe trends over time, and also compare specific sectors. In doing so, we can predict which industries have the best chance to recover economically from the pandemic (or any other economic incident that may occur).

UK Natural Medicine inventionINDEX Scores – Last 12 Months

The UK Natural Medicine inventionINDEX for April 2026 has reached a five-year low of 1.05 percent, resulting in a C rating. This performance indicates a sharp contraction in innovative activity within the sector compared to the preceding month, where the index stood at a more robust 1.62 percent with a B+ rating. Throughout the start of 2026, the index has struggled to find stability, fluctuating from a C+ in January to the current decline. When compared to April 2025, which saw a score of 1.58 percent, the current data suggests that the UK’s natural medicine innovation landscape is facing a significant cooling period characterized by reduced output in botanical intellectual property, natural therapeutics, and holistic advancements.

A longitudinal review of the last sixty months highlights a concerning trend of regression from previous periods of high productivity. The UK Natural Medicine index reached its historical peak in October 2023 with a score of 2.31 percent and an A+ rating, followed by another strong showing in January 2024 at 2.03 percent. The current score of 1.05 percent represents a stark departure from those elite-tier performances, marking the lowest point in the entire sixty-month data set. This transition from consistent A and B ratings into the C territory suggests that the momentum which fueled the post-2023 botanical and alternative medicine innovation boom has dissipated, leaving the UK’s natural health ecosystem in a state of marked deceleration.

The positive outcomes associated with a higher grade on the inventionINDEX are essential for long-term sector health and global leadership in complementary medicine. When the index reaches the A or A+ range, it signals a high-velocity environment for phytotherapy and nutritional research and development, efficient patent commercialization of natural extracts, and strong institutional support for emerging holistic therapies. Such scores act as a catalyst for significant venture capital inflows and encourage the growth of wellness and bioscience sectors that provide the foundation for future health industries. Maintaining a top-tier rating ensures that the UK remains a primary destination for global naturopathic talent and continues to set the standard for scientific and creative progress in alternative therapies on the world stage.

Conversely, a lower score or a sustained residence in the C category carries heavy negative implications for the UK’s competitiveness in the global natural health market. A declining index often serves as a leading indicator of stagnation in key supplement and alternative medicine sectors, and a potential bottleneck in the transition from laboratory discovery to market application for natural remedies. If these lower ratings persist, they can lead to a reduction in private sector R&D investment and a possible talent drain as natural medicine innovators seek more dynamic regulatory and commercial environments elsewhere. Addressing the factors behind this downward trend is vital to prevent a cycle of diminished economic vitality and to ensure that the infrastructure supporting the next generation of holistic breakthroughs is properly revitalized.

Discussion:

In April, the UK Natural Medicine inventionINDEX scored a positive sentiment which was lower than the previous year’s average and underperformed the downward trend for the year. This is similar to the prior 12 months, which experienced a slight downward trend.

As the UK economy continues to stabilize in the post-pandemic era, it remains uncertain whether any backlog of natural compound patent applications still exists with the Intellectual Property Office (IPO), or if the department has returned to normal processing timelines. The inventionINDEX could also be affected by lingering consequences from the pandemic, such as holistic clinic closures, reduced research workforces, disrupted botanical supply chains, and limited R&D capabilities, which may still be impacting current operations across the UK natural medicine sector.